Skip to content
2000
Volume 18, Issue 3
  • ISSN: 1389-2029
  • E-ISSN: 1875-5488

Abstract

Papillary microcarcinoma of the thyroid (mPTC) is defined by the WHO as a papillary thyroid cancer measuring 10mm or less in diameter and it is nowadays a topic of intense debate among the members of the medical community due to its apparent “epidemic” rise. Although these tumors follow almost always an indolent clinical course and carry an excellent prognosis, it is known that a small subset may display a potentially aggressive behavior. Nevertheless, we still lack an accurate way of predicting those which will cause significant disease. In an attempt to address this problem, a number of clinico-pathologic features have been studied as poor prognostic markers in mPTC, and their association with known genetic alterations in thyroid cancer has been evaluated. Herein we review the present knowledge concerning mPTC's genetic profile, namely the prevalence of BRAF (V600E), RAS and TERT promoter mutations and RET/PTC and PAX8-PPARG rearrangements and report the results of the evaluation in the putative prognostic value of these genetic alterations in mPTC.

Loading

Article metrics loading...

/content/journals/cg/10.2174/1389202918666170105094459
2017-06-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/cg/10.2174/1389202918666170105094459
Loading

  • Article Type:
    Research Article
Keyword(s): BRAF; Genetics; mPTC; Papillary microcarcinoma of the thyroid; Prognosis; RAS; RET/PTC; TERT
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test